OBJECTIVE： To observe the influence of Sijunzi decoction and Yupingfeng powder on the expression of the relevant DNAs of janus kinase （JAK）-signal transducer and activator of transcription （STAT） sig- nal pathway...OBJECTIVE： To observe the influence of Sijunzi decoction and Yupingfeng powder on the expression of the relevant DNAs of janus kinase （JAK）-signal transducer and activator of transcription （STAT） sig- nal pathway of the brain in spleen-deficiency mod- el rats. METHODS： Eighty male Wistar rats of sanitary degree were divided randomly into four groups： nor- mal group, model group, treatment group 1, treatment group 2. Besides the rats in the normal group, all the rats in other 3 groups were prepared as spleen deficiency model. The treatment group 1 were treated with Sijunzi decoction and the treat- ment group 2 were treated with Yupingfeng powder. After treatment for 6 weeks, perfusion was given and the brain was taken for detection of the ex- pression of the relevant DNAs of JAK-STAT signal pathwayofthe brain in SD rats bygene chip method. RESULTS： Spleen deficiency could lead to increase expression of JAKI, STATI and Interleukin 4 （IL-4） in the brain, but the decrease expression of Suppres- sor of cytokine signaling I （SOCSI）, prolactin recep- tor （PRLR） and binding protein 3 （GATA 3）. Sijunzi decoction could increase expression of STAT3, Pro- lactin （PRL） and GATA3, but decrease expression of JAKI, STAT, STAT4, Interleukin 10 receptor, alpha （ILIORA）, Coagulation factor II （F2）, PRLR, MAD homolog 3 （SMAD3） and IL-4. Yupingfeng powder could decrease expression of JAKI, STATI, STAT4, SOCS4_ predicted, Epidermal growth factor receptor （EGFR）, PRLR, High mobility group AT-hook I （HMGAI 0）, IL-4. CONCLUSION： Sijunzi decoction and Yupingfeng powder can improve immune function of the rat through influencing the genetic expression of JAK-STAT signal pathway.展开更多
Objective:To systematically evaluate the effect and safety of additional Yupingfeng powder combined with western medicine for the stable period of chronic obstructive pulmonary disease(COPD).Method:Databases including...Objective:To systematically evaluate the effect and safety of additional Yupingfeng powder combined with western medicine for the stable period of chronic obstructive pulmonary disease(COPD).Method:Databases including Pubmed、Web of Science、Cochrane Library、CNKI、VIP、CBM and Wanfang Data base,were searched for relevant randomized controlled trials.for Chinese and English literature about randomized controlled trials of additional Yupingfeng in the treatment of COPD on stable stage which were published from the establishment of the database to December 2019.Two researchers independently screened for,selected studies according to the inclusion and exclusion criteria and extracted data.Methodological quality was evaluated using the Cochrane Risk of Bias tool.Meta-analysis was performed using Revman 5.3 software.Results:Ninetine randomized controlled trials including 1511 patients with COPD were meta-analyzed.The total sample size was 1511.The results showed that the treatment grop with additional Yupingfeng powder could improve the clinical efficacy[OR=0.26,95%CI(0.18,0.37)],FEV1 percentage of the estimated value[MD=4.61,95%CI(2.43,6.79)],6MWD[MD=43.90,95%CI(29.48,58.32)]and patient's immunity IgA[MD=0.25,95%CI(0.17,0.34)]and can mitigate cough effectively[MD=-0.34,95%CI(-0.46,-0.23)].Conclusion:Additional Yupingfeng powder combined with routine treatment for COPD has more advantages than conventional treatment alone in improving the clinical efficacy,lung function,immune function and have less adverse events.As most of the included studies in this systematic evaluation had poor quality,the evidence to support conclusion was weak,so it was necessary to conduct more multi-center clinical trials with high quality methods and rigorous design.展开更多
Objective:The mechanism of Yupingfeng Powder in the treatment of non-small cell lung cancer was analyzed by network pharmacology and molecular docking method.Methods:Search the related literature and TCMSP database,qu...Objective:The mechanism of Yupingfeng Powder in the treatment of non-small cell lung cancer was analyzed by network pharmacology and molecular docking method.Methods:Search the related literature and TCMSP database,query the chemical composition and action target of Yupingfeng powder,query the disease database of Genecards,OMIM,DisGeNET,Drugbank,etc.,use"non-small cell lung cancer"as the keyword to search the disease-related target,select the intersection target with Yupingfeng powder as the research target,and use Cytoscape 3.7.2 software to construct the active component-target network map.The protein-protein interaction network map was constructed by using STRING database,and the treatment core targets were further screened by topological parameters,and GO analysis and KEGG signal pathway enrichment analysis were carried out.Finally,molecular docking was verified.Results:37 active components of Yupingfeng Powder were screened,including 146 common targets and 44 core targets.GO analysis and KEGG analysis show that the core target participates in many biological processes such as angiogenesis and cell proliferation,and acts on a variety of signal pathways such as AGE-RAGE,IL-17,TNF,MAPK and so on.Molecular docking shows that the core compound has good docking activity with the target.Conclusion:Network pharmacological analysis shows that Yupingfeng powder in the treatment of non-small cell lung cancer involves multi-target and multi-pathway mechanism,and the drug and target have good docking activity,which can provide theoretical basis for follow-up experimental research.展开更多
Yupingfeng Powder is widely used in the treatment of respiratory,digestive,urinary,dermatological and ENT diseases.The author reviewed the animal pharmacology experiments and clinical cases in recent years,and summari...Yupingfeng Powder is widely used in the treatment of respiratory,digestive,urinary,dermatological and ENT diseases.The author reviewed the animal pharmacology experiments and clinical cases in recent years,and summarized and analyzed the diseases he treated,providing ideas and methods for clinical users.展开更多
Objective:To use Meta-analysis to evaluate the effectiveness and safety of Yupingfeng Powder(YPFP)in regulating the immune function of patients with chronic obstructive pulmonary disease.Methods:Computers were used to...Objective:To use Meta-analysis to evaluate the effectiveness and safety of Yupingfeng Powder(YPFP)in regulating the immune function of patients with chronic obstructive pulmonary disease.Methods:Computers were used to search databases such as China National Knowledge Infrastructure(CNKI),VIP Database,China Biology Medicine disc(CBMdisc),Wanfang Database,PubMed,Cochrane Library,etc.Search all randomized controlled trials(RCTs)of YPFP in the treatment of stable chronic obstructive pulmonary disease,with CD4,CD8,CD4/CD8,IgE,IgA,IgM,and IgG as the outcome indicators.Two reviewers independently conducted literature search,conducted literature quality evaluation with the risk bias assessment tool recommended by Cochrane Handbook,and conducted data extraction,discussed and resolved disputes,and used RevMan 5.3 software for Meta-analysis.Results:A total of 11 randomized controlled trials with 1,058 patients were included.According to the Meta-analysis,the results of the effectiveness analysis showed that after oral administration of YPFP in the stable phase of chronic obstructive pulmonary disease,the test group CD3,CD4,CD8,CD4/CD8,IgA,IgE,IgM,IgG8 were better than the control group(P<0.05).Conclusion:Oral administration of YPFP in the stable period of chronic obstructive pulmonary disease can effectively regulate the immunity.However,the number of studies included in this study is small and the heterogeneity is large,and it is still necessary to design high-quality clinical trials for in-depth research.展开更多
Objective:Yupingfeng Powder(YPF),a kind of preventative patent medicine,is chosen for treatment of coronavirus disease 2019(COVID-19)due to its high frequency application in respiratory tract diseases,such as chronic ...Objective:Yupingfeng Powder(YPF),a kind of preventative patent medicine,is chosen for treatment of coronavirus disease 2019(COVID-19)due to its high frequency application in respiratory tract diseases,such as chronic obstructive pulmonary disease,asthma,respiratory tract infections,and pneumonia,with the advantage of reducing the relapse rate and the severity.However,the active components of YPF and the mechanisms of components affecting COVID-19 are unclear.This study aimed to determine active constituents and elucidate its potential mechanisms.Methods:Ultra performance liquid chromatography-quadrupole-time of flight mass spectrometry(UPLCQ/TOF-MS)and liquid chromatography-triple quadrupole mass spectrometry(LC-QQQ-MS)were used to determine the components and absorbable constituents of YPF.Secondly,TCMSP,Drugbank,Swiss and Pharm Mapper were used to search the targets of absorbable bioactive constituents of YPF,and the targets of COVID-19 were identified based on Gene Cards and OMIM databases.STRING database was used to filter the possible inter-protein interactions.Thirdly,Gene Ontology(GO)enrichment analysis and Kyoto Encyclopedia of Genes and Genomes(KEGG)pathways analysis were performed to identify molecular function and systemic involvement of target genes.Results:A total of 61 components of YPF and 36 absorbable constituents were identified through UPLC-Q/TOF-MS.Wogonin,prim-O-glucosylcimifugin,5-O-methylvisamminol,astragalosideⅣand 5-Omethylvisamminol(hydroxylation)were vital constituents for the treatment of COVID-19,and RELA,TNF,IL-6,MAPK14 and MAPK8 ere recognized as key targets of YPF.The major metabolic reactions of the absorbed constituents of YPF were demethylation,hydroxylation,sulfation and glucuronidation.GO and KEGG pathway analysis further showed that the most important functions of YPF were T cell activation,response to molecule of bacterial origin,cytokine receptor binding,receptor ligand activity,cytokine activity,IL-17 signaling pathway,Chagas disease,lipid and atherosclerosis,etc.Conclusion:The approach of combining UPLC-Q/TOF-MS with network pharmacology is an effective tool to identify potentially bioactive constituents of YPF and its key targets on treatment of COVID-19.展开更多
To observe the impact of Yupingfengsan Oral Liquid on the expression of IL-4 and IFN-<em>γ</em> in AR mice’s serum and expression level of nuclear factor—<em>κ</em>B (NF-<em>κ</em...To observe the impact of Yupingfengsan Oral Liquid on the expression of IL-4 and IFN-<em>γ</em> in AR mice’s serum and expression level of nuclear factor—<em>κ</em>B (NF-<em>κ</em>B) protein and gene in nasal mucosa. <strong>Method:</strong> Forty BALB/c mice were randomly divided into the normal group, model group, Yupingfengsan Oral Liquid group (6 g/kg) and Loratadine group, with 10 mice per group. AR mice model was established by OVA, and IL-4 and IFN-<em>γ</em> contents can be measured with ELISA. The morphological changes of nasal mucosa were observed by hematoxylin eosin (HE) staining and NF-<em>κ</em>B expression in the nasal mucosa of mice was tested with Real-Time PCR and Western blot. <strong>Results:</strong> Compared with the model group, the nasal symptoms in the Yupingfengsan Oral Liquid group and Loratadine group were obviously relieved. HE staining showed that there was a little inflammatory cell infiltration in the nasal mucosa of Yupingfengsan Oral Liquid group and Loratadine group and it was significantly reduced when compared with the model group. IL-4 level in the serum and expression of NF-<em>κ</em>B protein and gene in the nasal mucosa was consistent and it was decreased when compared with the model group (P < 0.01), but the IFN-<em>γ</em> level in the serum was increased (P < 0.01). <strong>Conclusion:</strong> Yupingfengsan Oral Liquid can improve the clinical symptoms and histopathological manifestations of AR mice sensitized by OVA, inhibit the NF-<em>κ</em>B expression, balance the percentage of Th1/Th2 cells, increase the IFN-<em>γ</em> level in the serum and decrease the IL-4 level.展开更多
目的研究玉屏风散对变应性鼻炎(allergic rhinitis,AR)患者辅助性T细胞(helper T cell,Th)1/Th17免疫失衡及肠道菌群的调节作用。方法以2023年4月至2024年11月陕西中医药大学附属医院收治的104例AR患者作为研究对象。采用随机数字表法...目的研究玉屏风散对变应性鼻炎(allergic rhinitis,AR)患者辅助性T细胞(helper T cell,Th)1/Th17免疫失衡及肠道菌群的调节作用。方法以2023年4月至2024年11月陕西中医药大学附属医院收治的104例AR患者作为研究对象。采用随机数字表法分为研究组和对照组,各52例。对照组予以常规治疗,研究组在对照组的基础上联合应用玉屏风散治疗,2组均治疗4周。比较2组的临床疗效、Th1细胞因子[白介素(interleukin,IL)-2和干扰素-γ]、Th17细胞因子(IL-17A和IL-22)、免疫球蛋白E、嗜酸性粒细胞、肠道菌群计数,以及鼻部症状总评分(total nasal symptom score,TNSS)、鼻结膜炎相关生活质量问卷(rhinoconjunctivitis quality of life questionnaire,RQLQ)评分以及匹兹堡睡眠质量指数(Pittsburgh sleep quality index,PSQI)评分。结果治疗4周后,研究组的总有效率较对照组更高(P<0.05);研究组的IL-17A、IL-22、免疫球蛋白E、嗜酸性粒细胞水平低于对照组,IL-2、干扰素-γ高于对照组(P<0.05);研究组的大肠埃希菌计数低于对照组,乳酸杆菌和双歧杆菌计数高于对照组(P<0.05)。治疗2周和4周后,研究组的TNSS评分、RQLQ评分和PSQI评分均低于对照组(P<0.05)。结论玉屏风散治疗AR患者的疗效显著,能纠正Th1/Th17免疫失衡,并调节肠道菌群,改善生活质量和睡眠质量。展开更多
基金Supported by State Natural Science Fund (No. 30772685)
文摘OBJECTIVE： To observe the influence of Sijunzi decoction and Yupingfeng powder on the expression of the relevant DNAs of janus kinase （JAK）-signal transducer and activator of transcription （STAT） sig- nal pathway of the brain in spleen-deficiency mod- el rats. METHODS： Eighty male Wistar rats of sanitary degree were divided randomly into four groups： nor- mal group, model group, treatment group 1, treatment group 2. Besides the rats in the normal group, all the rats in other 3 groups were prepared as spleen deficiency model. The treatment group 1 were treated with Sijunzi decoction and the treat- ment group 2 were treated with Yupingfeng powder. After treatment for 6 weeks, perfusion was given and the brain was taken for detection of the ex- pression of the relevant DNAs of JAK-STAT signal pathwayofthe brain in SD rats bygene chip method. RESULTS： Spleen deficiency could lead to increase expression of JAKI, STATI and Interleukin 4 （IL-4） in the brain, but the decrease expression of Suppres- sor of cytokine signaling I （SOCSI）, prolactin recep- tor （PRLR） and binding protein 3 （GATA 3）. Sijunzi decoction could increase expression of STAT3, Pro- lactin （PRL） and GATA3, but decrease expression of JAKI, STAT, STAT4, Interleukin 10 receptor, alpha （ILIORA）, Coagulation factor II （F2）, PRLR, MAD homolog 3 （SMAD3） and IL-4. Yupingfeng powder could decrease expression of JAKI, STATI, STAT4, SOCS4_ predicted, Epidermal growth factor receptor （EGFR）, PRLR, High mobility group AT-hook I （HMGAI 0）, IL-4. CONCLUSION： Sijunzi decoction and Yupingfeng powder can improve immune function of the rat through influencing the genetic expression of JAK-STAT signal pathway.
基金National Science and Technology Major Projects of Sudden Severe Acute Respiratory Infectious Diseases Treatment New Technology research and the New Scheme(No.2017 zx10204401)。
文摘Objective:To systematically evaluate the effect and safety of additional Yupingfeng powder combined with western medicine for the stable period of chronic obstructive pulmonary disease(COPD).Method:Databases including Pubmed、Web of Science、Cochrane Library、CNKI、VIP、CBM and Wanfang Data base,were searched for relevant randomized controlled trials.for Chinese and English literature about randomized controlled trials of additional Yupingfeng in the treatment of COPD on stable stage which were published from the establishment of the database to December 2019.Two researchers independently screened for,selected studies according to the inclusion and exclusion criteria and extracted data.Methodological quality was evaluated using the Cochrane Risk of Bias tool.Meta-analysis was performed using Revman 5.3 software.Results:Ninetine randomized controlled trials including 1511 patients with COPD were meta-analyzed.The total sample size was 1511.The results showed that the treatment grop with additional Yupingfeng powder could improve the clinical efficacy[OR=0.26,95%CI(0.18,0.37)],FEV1 percentage of the estimated value[MD=4.61,95%CI(2.43,6.79)],6MWD[MD=43.90,95%CI(29.48,58.32)]and patient's immunity IgA[MD=0.25,95%CI(0.17,0.34)]and can mitigate cough effectively[MD=-0.34,95%CI(-0.46,-0.23)].Conclusion:Additional Yupingfeng powder combined with routine treatment for COPD has more advantages than conventional treatment alone in improving the clinical efficacy,lung function,immune function and have less adverse events.As most of the included studies in this systematic evaluation had poor quality,the evidence to support conclusion was weak,so it was necessary to conduct more multi-center clinical trials with high quality methods and rigorous design.
基金Priority Theme Setting of Traditional Chinese Medicine for Malignant Tumor and Implementation Scheme Design of Evidence-based Research(No.K-858)Beijing Municipal Commission of Science and Technology(No.D161100005116001)。
文摘Objective:The mechanism of Yupingfeng Powder in the treatment of non-small cell lung cancer was analyzed by network pharmacology and molecular docking method.Methods:Search the related literature and TCMSP database,query the chemical composition and action target of Yupingfeng powder,query the disease database of Genecards,OMIM,DisGeNET,Drugbank,etc.,use"non-small cell lung cancer"as the keyword to search the disease-related target,select the intersection target with Yupingfeng powder as the research target,and use Cytoscape 3.7.2 software to construct the active component-target network map.The protein-protein interaction network map was constructed by using STRING database,and the treatment core targets were further screened by topological parameters,and GO analysis and KEGG signal pathway enrichment analysis were carried out.Finally,molecular docking was verified.Results:37 active components of Yupingfeng Powder were screened,including 146 common targets and 44 core targets.GO analysis and KEGG analysis show that the core target participates in many biological processes such as angiogenesis and cell proliferation,and acts on a variety of signal pathways such as AGE-RAGE,IL-17,TNF,MAPK and so on.Molecular docking shows that the core compound has good docking activity with the target.Conclusion:Network pharmacological analysis shows that Yupingfeng powder in the treatment of non-small cell lung cancer involves multi-target and multi-pathway mechanism,and the drug and target have good docking activity,which can provide theoretical basis for follow-up experimental research.
基金Granted by the Guangdong Provincial Bureau of Traditional Chinese Medicine(No.:20131155).
文摘Yupingfeng Powder is widely used in the treatment of respiratory,digestive,urinary,dermatological and ENT diseases.The author reviewed the animal pharmacology experiments and clinical cases in recent years,and summarized and analyzed the diseases he treated,providing ideas and methods for clinical users.
基金This research was supported by the Tianjin Health Commission,Tianjin Administration of Traditional Chinese Medicine-Traditional Chinese Medicine,and Integrated Traditional Chinese and Western Medicine Scientific Research Projects(No.2019031).
文摘Objective:To use Meta-analysis to evaluate the effectiveness and safety of Yupingfeng Powder(YPFP)in regulating the immune function of patients with chronic obstructive pulmonary disease.Methods:Computers were used to search databases such as China National Knowledge Infrastructure(CNKI),VIP Database,China Biology Medicine disc(CBMdisc),Wanfang Database,PubMed,Cochrane Library,etc.Search all randomized controlled trials(RCTs)of YPFP in the treatment of stable chronic obstructive pulmonary disease,with CD4,CD8,CD4/CD8,IgE,IgA,IgM,and IgG as the outcome indicators.Two reviewers independently conducted literature search,conducted literature quality evaluation with the risk bias assessment tool recommended by Cochrane Handbook,and conducted data extraction,discussed and resolved disputes,and used RevMan 5.3 software for Meta-analysis.Results:A total of 11 randomized controlled trials with 1,058 patients were included.According to the Meta-analysis,the results of the effectiveness analysis showed that after oral administration of YPFP in the stable phase of chronic obstructive pulmonary disease,the test group CD3,CD4,CD8,CD4/CD8,IgA,IgE,IgM,IgG8 were better than the control group(P<0.05).Conclusion:Oral administration of YPFP in the stable period of chronic obstructive pulmonary disease can effectively regulate the immunity.However,the number of studies included in this study is small and the heterogeneity is large,and it is still necessary to design high-quality clinical trials for in-depth research.
基金supported by the Natural Science Foundation of Zhejiang Province(No.LQ20H270008)Natural Science Foundation of Zhejiang Chinese Medical University(No.2018ZZ13)。
文摘Objective:Yupingfeng Powder(YPF),a kind of preventative patent medicine,is chosen for treatment of coronavirus disease 2019(COVID-19)due to its high frequency application in respiratory tract diseases,such as chronic obstructive pulmonary disease,asthma,respiratory tract infections,and pneumonia,with the advantage of reducing the relapse rate and the severity.However,the active components of YPF and the mechanisms of components affecting COVID-19 are unclear.This study aimed to determine active constituents and elucidate its potential mechanisms.Methods:Ultra performance liquid chromatography-quadrupole-time of flight mass spectrometry(UPLCQ/TOF-MS)and liquid chromatography-triple quadrupole mass spectrometry(LC-QQQ-MS)were used to determine the components and absorbable constituents of YPF.Secondly,TCMSP,Drugbank,Swiss and Pharm Mapper were used to search the targets of absorbable bioactive constituents of YPF,and the targets of COVID-19 were identified based on Gene Cards and OMIM databases.STRING database was used to filter the possible inter-protein interactions.Thirdly,Gene Ontology(GO)enrichment analysis and Kyoto Encyclopedia of Genes and Genomes(KEGG)pathways analysis were performed to identify molecular function and systemic involvement of target genes.Results:A total of 61 components of YPF and 36 absorbable constituents were identified through UPLC-Q/TOF-MS.Wogonin,prim-O-glucosylcimifugin,5-O-methylvisamminol,astragalosideⅣand 5-Omethylvisamminol(hydroxylation)were vital constituents for the treatment of COVID-19,and RELA,TNF,IL-6,MAPK14 and MAPK8 ere recognized as key targets of YPF.The major metabolic reactions of the absorbed constituents of YPF were demethylation,hydroxylation,sulfation and glucuronidation.GO and KEGG pathway analysis further showed that the most important functions of YPF were T cell activation,response to molecule of bacterial origin,cytokine receptor binding,receptor ligand activity,cytokine activity,IL-17 signaling pathway,Chagas disease,lipid and atherosclerosis,etc.Conclusion:The approach of combining UPLC-Q/TOF-MS with network pharmacology is an effective tool to identify potentially bioactive constituents of YPF and its key targets on treatment of COVID-19.
文摘To observe the impact of Yupingfengsan Oral Liquid on the expression of IL-4 and IFN-<em>γ</em> in AR mice’s serum and expression level of nuclear factor—<em>κ</em>B (NF-<em>κ</em>B) protein and gene in nasal mucosa. <strong>Method:</strong> Forty BALB/c mice were randomly divided into the normal group, model group, Yupingfengsan Oral Liquid group (6 g/kg) and Loratadine group, with 10 mice per group. AR mice model was established by OVA, and IL-4 and IFN-<em>γ</em> contents can be measured with ELISA. The morphological changes of nasal mucosa were observed by hematoxylin eosin (HE) staining and NF-<em>κ</em>B expression in the nasal mucosa of mice was tested with Real-Time PCR and Western blot. <strong>Results:</strong> Compared with the model group, the nasal symptoms in the Yupingfengsan Oral Liquid group and Loratadine group were obviously relieved. HE staining showed that there was a little inflammatory cell infiltration in the nasal mucosa of Yupingfengsan Oral Liquid group and Loratadine group and it was significantly reduced when compared with the model group. IL-4 level in the serum and expression of NF-<em>κ</em>B protein and gene in the nasal mucosa was consistent and it was decreased when compared with the model group (P < 0.01), but the IFN-<em>γ</em> level in the serum was increased (P < 0.01). <strong>Conclusion:</strong> Yupingfengsan Oral Liquid can improve the clinical symptoms and histopathological manifestations of AR mice sensitized by OVA, inhibit the NF-<em>κ</em>B expression, balance the percentage of Th1/Th2 cells, increase the IFN-<em>γ</em> level in the serum and decrease the IL-4 level.
文摘目的研究玉屏风散对变应性鼻炎(allergic rhinitis,AR)患者辅助性T细胞(helper T cell,Th)1/Th17免疫失衡及肠道菌群的调节作用。方法以2023年4月至2024年11月陕西中医药大学附属医院收治的104例AR患者作为研究对象。采用随机数字表法分为研究组和对照组,各52例。对照组予以常规治疗,研究组在对照组的基础上联合应用玉屏风散治疗,2组均治疗4周。比较2组的临床疗效、Th1细胞因子[白介素(interleukin,IL)-2和干扰素-γ]、Th17细胞因子(IL-17A和IL-22)、免疫球蛋白E、嗜酸性粒细胞、肠道菌群计数,以及鼻部症状总评分(total nasal symptom score,TNSS)、鼻结膜炎相关生活质量问卷(rhinoconjunctivitis quality of life questionnaire,RQLQ)评分以及匹兹堡睡眠质量指数(Pittsburgh sleep quality index,PSQI)评分。结果治疗4周后,研究组的总有效率较对照组更高(P<0.05);研究组的IL-17A、IL-22、免疫球蛋白E、嗜酸性粒细胞水平低于对照组,IL-2、干扰素-γ高于对照组(P<0.05);研究组的大肠埃希菌计数低于对照组,乳酸杆菌和双歧杆菌计数高于对照组(P<0.05)。治疗2周和4周后,研究组的TNSS评分、RQLQ评分和PSQI评分均低于对照组(P<0.05)。结论玉屏风散治疗AR患者的疗效显著,能纠正Th1/Th17免疫失衡,并调节肠道菌群,改善生活质量和睡眠质量。
